|Videos|December 26, 2022
Advances in Oral Insulin for the Management of Diabetes
Dr Diana Isaacs provides an overview of the latest developments in oral insulin to manage patients with diabetes.
Advertisement
Episodes in this series
Advertisement
Related to this article
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Advertisement
Advertisement
Trending on HCPLive
1
US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD
2
Nail Detachment 4 Times More Common With GLP-1 Use
3
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes
4
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
5